LL-37 vs KPV
LL-37 is mainly studied for innate defense, inflammatory balance. while KPV is studied for gut health, inflammation, recovery. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| LL-37 | KPV | |
|---|---|---|
| Category | Immune | Immune |
| Studied for | Innate defense, inflammatory balance. | Gut health, inflammation, recovery. |
| How it acts | An antimicrobial peptide studied for its relationship with innate defense and modulation of inflammatory processes. | A peptide fragment studied for its relationship with inflammation modulation, especially at the gut level. |
| Evidence level | Limited human evidence | Preclinical evidence only |
How they differ
Although sometimes mentioned together, LL-37 and KPV do not target the same thing. LL-37: An antimicrobial peptide studied for its relationship with innate defense and modulation of inflammatory processes. KPV: A peptide fragment studied for its relationship with inflammation modulation, especially at the gut level.
See full entry: LL-37 → · See full entry: KPV →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between LL-37 and KPV?
LL-37 targets innate defense, inflammatory balance. and KPV targets gut health, inflammation, recovery. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, LL-37 has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for LL-37 vs KPV or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trialhuman Wound Repair Regen · 2014 · PMID 25041740 →
- Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trialhuman Wound Repair Regen · 2021 · PMID 34687253 →
- LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activityreview Pharmacol Rep · 2016 · PMID 27117377 →
- LL-37, the only human member of the cathelicidin family of antimicrobial peptidesreview Biochim Biophys Acta · 2006 · PMID 16716248 →
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel diseasepreclinical Inflamm Bowel Dis · 2008 · PMID 18092346 →
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationpreclinical Gastroenterology · 2008 · PMID 18061177 →
- Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine modelpreclinical Cell Mol Gastroenterol Hepatol · 2016 · PMID 27458604 →
- Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitispreclinical Mol Ther · 2017 · PMID 28143741 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.